Nicox continues expansion of international distribution network with exclusive agreement for Australia and New Zealand
October 8, 2014
This press release is being reissued with a corrected forward-looking statement
Sophia Antipolis, France.
Nicox S.A. (NYSE Euronext Paris: COX), the international ophthalmic company, today announced that it has entered into an exclusive agreement with OptiMed, a leading Australian company distributing ophthalmic diagnostic and therapeutic products, for the distribution of its product portfolio, including AdenoPlus® and the Xailin™ range, in Australia and New Zealand. This further strengthens Nicox’s rapidly-growing international operations, with third-party agreements already established in Japan, Switzerland, Belgium, Netherlands, Luxemburg, Poland, Turkey and a number of countries in southern Africa.
“Our international product revenues are beginning to grow rapidly as we expand our network of best-in-class partners,” said Philippe Masquida, Executive Vice-President, Managing Director of European and International Operations at Nicox Pharma. “The finalization of the collaboration with OptiMed for the distribution of our products in Australia and New Zealand follows the recent partnership on AdenoPlus with Nitto Medic in Japan. Since the beginning of the year, we have established partnerships in more than 10 countries with well-established local players, complementing our own sales infrastructure in selected markets. We expect distribution partnerships to play a key role in our revenue growth, in both established and fast-growing emerging markets.”
Since the beginning of 2014, Nicox has signed a number of exclusive distribution agreements for its growing international product portfolio, with Medano AG in Switzerland; Simovision in Benelux (Belgium, Netherlands and Luxembourg); Liba Laboratuarlari A.S. in Turkey; Genop Healthcare in South Africa, Botswana, Namibia, Lesotho, Swaziland and Zimbabwe; and OptiMed in Australia and New Zealand. Nicox has also signed an exclusive distribution agreement for AdenoPlus® with Nitto Medic in Japan. In Poland, Nicox has appointed Sopharm to manage pre-marketing and market access activities. Nicox is working on securing distribution agreements in other key international markets in Asia, Latin America, Europe, Africa and the Middle-East.
Except for the agreement with Nitto Medic which is just focused on AdenoPlus®, these distribution agreements generally concern the full range of Nicox products (outside of North America), both marketed and in development, including: several in vitro diagnostic medical devices in-licensed from RPS®, such as AdenoPlus® to aid in the differential diagnosis of acute conjunctivitis; Xailin™, a range of tear lubricants for the relief of dry eye symptoms (classed as medical devices); and future products from Nicox’s internal development program. Nicox currently markets AdenoPlus® and the Xailin™ range with its own sales force in the five main European markets (France, Germany, Italy, Spain and the UK).